Market Overview:
The global erythropoietin (EPO) drugs market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of anemia and kidney disorders, and rising demand for EPO drugs in emerging countries. Based on type, the EPO drugs market is segmented into epoetin-alfa, darbepoetin-alfa, epoetin-beta and others. Epoetin-alpha dominates the EPO drugs market due to its high efficiency in treating anemia caused by various diseases such as cancer and chronic renal failure (CRF). Based on application, the EPO drugs market is segmented into anemia, kidney disorders and other applications. Anemia accounts for a major share of the EPO drugs market owing to its high prevalence across geographies. Kidney disorders are also one of the key drivers for thismarket as they are associated with several health complications that can be treated withEPOsolutions effectively .
 Drugs Industry Outlook.svg)
Product Definition:
A hormone that stimulates the production of red blood cells in the bone marrow.
Epoetin-alfa:
Epoetin-alfa is a form of human erythropoietin (EPO). It is produced by kidney and liver cells. Epoetin-alfa has the ability to stimulate the production of red blood cells by the bone marrow. The increased number of red blood cells has a greater capacity to carry oxygen to tissues, which helps in preventing anemia.
Darbepoetin-alfa:
Darbepoetin-alfa is a type of erythropoietin (EPO) drug developed by the Swiss company, Roche. It was approved in Japan in November 2007 and received FDA approval for U.S. market-entry in March 2008 as the single source of epoetin oncology treatment; it has been prescribed to over 2 million patients since its launch till date.
Application Insights:
Anemia was the dominant application segment in terms of revenue share in 2017. An increase in the prevalence of anemia is one of the key drivers for increasing demand for erythropoietin-stimulating agents (ESAs). According to data published by WHO, globally, approximately 38% to 45% people aged over 15 years suffer from some degree of anemia. In addition, as per data published by ESRD Foundation, it is estimated that around 10 million individuals are living with chronic kidney disease (CKD) worldwide and this number is expected to reach 20 million by 2030. These factors are anticipated to boost demand for erythropoietin-stimulating agents during the forecast period.
The other applications segment includes indications other than anemic disorders such as neurological disorders and kidney disorders wherein ESAs have been found effective remedies.
Regional Analysis:
North America dominated the global market in 2017 owing to favorable government initiatives and increasing awareness about erythropoietin drugs. Moreover, high healthcare expenditure and presence of major manufacturers in this region are anticipated to drive the regional market over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period due to rising disposable income, improving economic conditions, expanding patient pool for kidney disorders due to aging demographics, and growing awareness about erythropoietin drugs among patients. In addition, untapped opportunities for new product development by companies as well as a large base of target population present across this region will support its growth over next eight years.
In China alone more than 50 million people suffer from anemia which requires regular treatment with Ery-poeitin drug combination products such as Epogen or Procrit (ephapan).
Growth Factors:
- Increasing incidence of anemia: The increasing incidence of anemia is a major growth driver for the erythropoietin drugs market. Anemia is a condition in which there is a deficiency of red blood cells or hemoglobin in the blood, resulting in symptoms such as fatigue, shortness of breath, and dizziness. According to the World Health Organization (WHO), an estimated 2 billion people are affected by some form of anemia worldwide. This number is expected to increase due to the rising prevalence of lifestyle diseases such as obesity and diabetes mellitus.
- Growing demand for erythropoietin drugs in emerging markets: The growing demand for erythropoietin drugs in emerging markets is another key growth driver for this market. Emerging markets such as China and India are experiencing rapid economic growth, which has led to an increase in the number of people who can afford expensive medical treatments such as erythropoietin drugs therapy. Furthermore, these countries have large populations that are at risk for developing anemia due to various factors such as malnutrition and parasitic infections.
Scope Of The Report
Report Attributes
Report Details
Report Title
Erythropoietin (EPO) Drugs Market Research Report
By Type
Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta, Others
By Application
Anemia, Kidney Disorders, Other
By Companies
Amgen, Johnson & Johnson, Roche, Galenica, Emcure, Kyowa Hakko Kirin, SBio, Biocon, LG Life Sciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
184
Number of Tables & Figures
129
Customization Available
Yes, the report can be customized as per your need.
Global Erythropoietin (EPO) Drugs Market Report Segments:
The global Erythropoietin (EPO) Drugs market is segmented on the basis of:
Types
Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Anemia, Kidney Disorders, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Johnson & Johnson
- Roche
- Galenica
- Emcure
- Kyowa Hakko Kirin
- SBio
- Biocon
- LG Life Sciences
 Drugs Market Overview.svg)
Highlights of The Erythropoietin (EPO) Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Epoetin-alfa
- Darbepoetin-alfa
- Epoetin-beta
- Others
- By Application:
- Anemia
- Kidney Disorders
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Erythropoietin (EPO) Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Drugs Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
EPO drugs are medications that stimulate the body's production of erythropoietin (EPO). EPO is a hormone that helps the body produce red blood cells. EPO drugs can help people with anemia to improve their blood flow and oxygen levels.
Some of the major companies in the erythropoietin (epo) drugs market are Amgen, Johnson & Johnson, Roche, Galenica, Emcure, Kyowa Hakko Kirin, SBio, Biocon, LG Life Sciences.
The erythropoietin (epo) drugs market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Erythropoietin (EPO) Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Erythropoietin (EPO) Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Erythropoietin (EPO) Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Erythropoietin (EPO) Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Erythropoietin (EPO) Drugs Market Size & Forecast, 2020-2028
4.5.1 Erythropoietin (EPO) Drugs Market Size and Y-o-Y Growth
4.5.2 Erythropoietin (EPO) Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Epoetin-alfa
5.2.2 Darbepoetin-alfa
5.2.3 Epoetin-beta
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Anemia
6.2.2 Kidney Disorders
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Erythropoietin (EPO) Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Erythropoietin (EPO) Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Epoetin-alfa
9.6.2 Darbepoetin-alfa
9.6.3 Epoetin-beta
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Anemia
9.10.2 Kidney Disorders
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Epoetin-alfa
10.6.2 Darbepoetin-alfa
10.6.3 Epoetin-beta
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Anemia
10.10.2 Kidney Disorders
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Epoetin-alfa
11.6.2 Darbepoetin-alfa
11.6.3 Epoetin-beta
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Anemia
11.10.2 Kidney Disorders
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Epoetin-alfa
12.6.2 Darbepoetin-alfa
12.6.3 Epoetin-beta
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Anemia
12.10.2 Kidney Disorders
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Epoetin-alfa
13.6.2 Darbepoetin-alfa
13.6.3 Epoetin-beta
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Anemia
13.10.2 Kidney Disorders
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Erythropoietin (EPO) Drugs Market: Competitive Dashboard
14.2 Global Erythropoietin (EPO) Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Johnson & Johnson
14.3.3 Roche
14.3.4 Galenica
14.3.5 Emcure
14.3.6 Kyowa Hakko Kirin
14.3.7 SBio
14.3.8 Biocon
14.3.9 LG Life Sciences
